Brubru
EU policy intelligence
Directive 2001/83/EC is the horizontal rulebook for every medicine not going through the centralised EMA route. A codification of 11 prior directives, it governs the complete lifecycle: national and mutual-recognition marketing authorisation, manufacturing, labelling, advertising, pharmacovigilance, and supervision.
The directive half of EU medicines law, and the backbone of the decentralised system
EU medicines law for human use rests on two complementary instruments. Regulation (EC) No 726/2004 governs products authorised centrally via the EMA: one application, one CHMP opinion, one Commission decision valid EEA-wide. Directive 2001/83/EC is the other pillar: the harmonised national baseline that governs every medicine authorised at Member State level through the national, mutual-recognition or decentralised procedure. Where 726/2004 is the centralised spine, 2001/83 is the horizontal rulebook underpinning the decentralised system.
Even centrally authorised products are not free of the Code: its definitions (Title I), labelling requirements (Title V), classification provisions (Title VI), wholesale distribution obligations (Title VII), advertising rules (Title VIII) and pharmacovigilance framework (Title IX) apply across all authorisation routes. The Code thus touches every medicine that reaches EU patients.
The directive was adopted under Article 95 TEC (now Art 114 TFEU), the internal market approximation provision, via the co-decision procedure of Art 251 TEC. The legal basis reflects the directive's core purpose: eliminating distortions caused by divergent national rules on the conditions under which medicinal products are placed on the market. It was signed in Brussels on 6 November 2001 by EP President Nicole Fontaine and Belgian Council Presidency Minister Didier Reynders, and published in OJ L 311 on 28 November 2001.
The directive entered into force on the 20th day after its publication in the OJ (Art 129), but as a codification it set no fresh transposition deadline for Member States: Annex II Part B preserved the original transposition deadlines of the eleven directives it repealed.
The directive is structured into 61 recitals explaining the legislative purposes and 14 Titles containing 130 articles. Three Annexes complete the instrument: Annex I sets the standards for analytical, pharmacotoxicological and clinical dossiers; Annex II lists the repealed directives and their transposition deadlines; Annex III is a correlation table mapping each article of the Code to its predecessor in the eleven repealed directives. The directive has subsequently been amended by five further directives (2004/24, 2004/27, 2010/84, 2011/62, 2012/26) and is now the subject of a proposed replacement under the 2023 pharma reform (as amended).
Recital 1 and Art 128: the eleven predecessor directives repealed in 2001
Recital 1 states that Directive 2001/83/EC is "a codification" adopted in the interests of clarity and rationality. It assembled eleven pre-existing directives spanning 36 years of EU medicines law into a single coherent text. Article 128 formally repeals them, while Annex II Part B preserves their original transposition deadlines so that Member States' existing obligations were not disrupted. The eleven repealed instruments were:
Art 1: 28 defined terms forming the vocabulary of EU medicines regulation
Article 1 contains the full lexicon of the Community Code: 28 numbered definitions used throughout EU medicines law. Key definitions include:
The directive applies to industrially produced human medicines, subject to important exemptions
The MA requirement, application content, the 210-day procedure, and the homeopathic simplified registration
Article 6 states the fundamental rule: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authority of that Member State in accordance with the directive, or an authorisation has been granted in accordance with Regulation 726/2004. There are no exceptions to this principle within the industrial scope of the directive.
The MA holder must be established in the Community (Art 8). Where the MA holder is not the manufacturer, the holder must designate a person within the Community responsible for pharmacovigilance.
An application for MA must include: details of the applicant, the name of the product, qualitative and quantitative particulars of all active substances and excipients, description of manufacturing method, therapeutic indications, contraindications and adverse reactions, posology and method of administration, precautions and safety measures, particulars of shelf life and storage conditions, and the analytical, pharmacotoxicological and clinical tests in accordance with Annex I.
A key deliverable is the Summary of Product Characteristics (SmPC) (Art 11), which sets out the product's approved properties: name, composition, pharmaceutical form, clinical particulars (indications, dosage, contraindications, warnings, interactions, adverse effects, overdose), pharmacological and pharmaceutical properties, and regulatory information. The SmPC is the authoritative scientific reference document for healthcare professionals and forms the basis for the package leaflet.
Once the competent authority of a Member State receives a valid application, it must take a decision within 210 days (Art 17). During the assessment, the authority may require the applicant to supply additional information; the clock stops until the information is received. The authority may also consult the EMA's scientific committees. The 210-day standard national clock mirrors the CHMP procedure of 726/2004, creating procedural parity across authorisation routes.
If the competent authority considers that the application raises issues of public or animal health of general Community interest, it may refer the matter to the Committee for Proprietary Medicinal Products (CPMP, now CHMP) before a decision is taken (Art 29, referral procedure).
In the original 2001 text, Art 24 set MA validity at 5 years, renewable for further 5-year periods. Directive 2004/27/EC amended Art 24 so that after the first 5-year renewal, the MA becomes unlimited in duration unless the competent authority decides, on justified grounds relating to pharmacovigilance, that a further 5-year renewal is necessary. The sunset clause (Art 24(4)-(5)) provides that an MA lapses if not exercised within 3 years of grant, or if the authorised product is absent from the market for 3 consecutive years (as amended).
Homeopathic medicinal products that meet all the following conditions may use a simplified registration procedure: they are administered orally or externally; they present no specific therapeutic indication on the labelling or documentation; and there is a sufficient degree of dilution to guarantee safety. The procedure does not require clinical tests; the applicant need only demonstrate that the product is sufficiently dilute and that the starting material is described in an official pharmacopoeia. Traditional-herbal products (Arts 16a to 16i, inserted by Dir 2004/24) follow a separate but analogous simplified route supervised by the Herbal Medicinal Products Committee (HMPC).
How generic manufacturers rely on the innovator's data, and the 8+2+1 protection formula introduced by Dir 2004/27
Article 10, as substantially amended by Directive 2004/27, is the legal basis for generic medicines in the decentralised system. An applicant for a generic medicine need not provide the results of pre-clinical and clinical tests if it can demonstrate that the medicine is a generic of a reference medicinal product that has been authorised for at least 8 years in a Member State or the Community.
The art 10 abridged route also covers: the "well-established medicinal use" bibliographic route (Art 10a) for substances in use in the Community for at least 10 years; the fixed-dose combination route (Art 10b); and the informed consent route where a previous dossier holder consents to use of their data (Art 10c). Each of these routes was reorganised and clarified by Directive 2004/27 to reduce fragmentation across Member States.
In the original 2001 text, Art 10 provided data protection of 6 years (10 years for high-technology/biotechnology products) before generic applicants could rely on the innovator's data. Directive 2004/27/EC replaced this with the harmonised 8+2+1 formula applicable across all routes:
The maximum combined protection period is 11 years. The 8+2+1 formula applies equally under the centralised procedure (via Art 14(11) of 726/2004) and the national/decentralised routes governed by 2001/83 Art 10.
How a national MA in one Member State translates into recognition across the EU, and the CPMP referral mechanism
Where an applicant has already obtained a national MA in one Member State (the Reference Member State, RMS) and wishes to extend it to one or more other Member States (Concerned Member States, CMS), they may apply through the mutual-recognition procedure. The CMS must normally recognise the existing RMS authorisation within 90 days of receiving the assessment report, SmPC, labelling and package leaflet from the RMS. If the CMS raises no objection, the MA is granted on the same terms as in the RMS.
If a CMS raises a serious potential risk to public health that cannot be resolved between the RMS and CMS, the matter is referred to the CPMP (now CHMP) under the referral procedure of Arts 29 to 34 for a binding Community-level resolution.
Where an applicant seeks MAs in several Member States simultaneously for a product not yet authorised anywhere in the EU, they may use the decentralised procedure (added to Art 28 by Dir 2004/27). One Member State acts as RMS and prepares the draft assessment report, draft SmPC, labelling and package leaflet. The CMS then have 210 days to agree. At the end of the procedure, each participating Member State grants a national MA with an identical SmPC, labelling and package leaflet.
The decentralised procedure therefore produces a set of nationally granted MAs (not a single Community authorisation) but with identical product information across all participating Member States, giving the commercial coverage of a near-Community authorisation while respecting national competences.
Where a Member State considers that there are grounds for considering that a medicinal product authorised by another MS presents a risk to public health, or where there is disagreement in the mutual-recognition procedure, the matter is referred to the CPMP for arbitration under Arts 29 to 34. The CPMP must deliver an opinion within 60 days (extendable to 90 days in complex cases). The Commission then adopts a decision in the Standing Committee (comitology) that is binding on all Member States. This referral mechanism was the central tool for resolving cross-border disagreements on risk-benefit assessments before CHMP opinions became binding via 726/2004 for centralised products.
The Community Code was adopted naming the Committee for Proprietary Medicinal Products (CPMP) as the body to which referrals were made and which coordinated the mutual-recognition network. Regulation (EC) No 726/2004 (Art 87) renamed the CPMP as the Committee for Medicinal Products for Human Use (CHMP) and anchored it within the EMA. References to the CPMP in the Community Code now read as references to the CHMP. Similarly, references to Regulation (EEC) No 2309/93 (the predecessor EMA regulation) in the Community Code read as references to Regulation (EC) No 726/2004.
Manufacturing authorisation, Good Manufacturing Practice, and the Qualified Person
No person may manufacture or import medicinal products from third countries without a manufacturing authorisation (Art 40). The competent authority must take a decision on the application within 90 days of receiving a valid application. The authorisation specifies the premises, pharmaceutical forms and categories of products covered. The holder must have at their disposal at least one Qualified Person (Art 41) and must comply with GMP at all times.
Holders of manufacturing authorisations must comply with the Good Manufacturing Practice (GMP) principles and guidelines established by the Commission under Art 47. GMP covers quality systems, premises and equipment, documentation, production, quality control, outsourced activities, complaints and recalls. The Commission publishes detailed GMP guidelines (EudraLex Volume 4); the obligation in the directive is to comply with those guidelines as a binding condition of the manufacturing authorisation.
The Qualified Person (QP) is a cornerstone of EU medicines manufacturing law. Every holder of a manufacturing authorisation must have at their disposal at least one QP (Art 48), and the QP may not be replaced without the prior authorisation of the competent authority (Art 50). The QP must be a person of good standing, possess a university diploma in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry, biology or equivalent, and have at least two years of practical experience in activities including qualitative analysis, quantitative analysis of active substances, and testing to ensure compliance with GMP.
The QP's core legal duty is set out in Art 51: each batch of medicinal product manufactured within the Community must have been certified by a QP as meeting the requirements of the MA and the applicable GMP standards. For products imported from third countries, the QP must certify that each batch has undergone a full qualitative analysis, a quantitative analysis of active substances, and all other tests or checks necessary to ensure quality, in accordance with MA requirements. No batch may be released for sale or supply unless certified by the QP. The QP is personally responsible for this certification.
Mandatory outer/immediate-packaging particulars, package leaflet content, and the official-language requirement
Article 54 lists the particulars that must appear on the outer packaging (and where there is no outer packaging, on the immediate packaging) of every medicinal product placed on the EU market. They include: the name of the product; the qualitative and quantitative composition in active substances; the pharmaceutical form and the contents by weight, volume or number of doses; the list of excipients that have a recognised action or effect; the method of administration and, if necessary, the route of administration; a special warning that the product must be stored out of the reach of children; a special warning, if necessary, for the product; the expiry date; the special storage precautions; the special precautions relating to the disposal of unused products; the name and address of the MA holder; the MA number; the manufacturer's batch number; and the patient information leaflet reference.
A package leaflet must be included in the packaging of every medicinal product unless all the required information appears on the outer/immediate packaging. Art 59 specifies the mandatory content: identification of the product; therapeutic indications; what the patient needs to know before taking the product; instructions for proper use; side effects; how to store the product; and further essential information. The leaflet must be written in clear and understandable terms for the patient and must be verified by patient-focus groups (Art 61(1), as amended by Dir 2004/27).
The labelling and package leaflet must be written in the official language(s) of the Member State(s) where the product is marketed (Art 63). Competent authorities may grant derogations for certain products intended for professional use only, and for products in clinical trials. This requirement ensures that patients and healthcare professionals receive product information in a language they understand, and it means that an MA holder marketing across multiple Member States must maintain language-specific packaging or inserts for each Member State.
Prescription vs non-prescription, and the criteria for sub-categories of prescription-only medicines
When granting an MA, competent authorities must classify the product as either subject to medical prescription or not subject to medical prescription (Art 70). Medicines must be subject to medical prescription if they are likely to present a danger, directly or indirectly, if used without medical supervision; are frequently and widely used incorrectly so as to present a direct or indirect danger; contain substances whose activity or adverse reactions require further investigation; or are normally prescribed by a doctor for parenteral administration (Art 71).
Within prescription-only medicines, Art 71 also defines sub-categories: those renewable only once, those indicating "restricted medical prescription" (due to dangerous pharmacological effects), and those subject to "special medical prescription" (for conditions requiring specific supervision, e.g. cytotoxics, immunosuppressants, hormones with potential abuse, or radiopharmaceuticals). Non-prescription medicines sold only in pharmacies form a further sub-category in some Member States.
As amended by Directive 2004/27, Art 74a introduced a specific Community procedure for switching medicines from prescription-only to non-prescription status (the "Rx-to-OTC switch"). The MA holder may apply for re-classification based on new safety data or a change in the risk-benefit balance after a product has been on the market for a sufficient period. The competent authority must consult with other Member States through the mutual-recognition network before granting a re-classification, ensuring that a switch approved in one Member State is consistently applied across the Community.
Wholesale distribution authorisation, Good Distribution Practice, the public service obligation, and recall plans
No person may engage in wholesale distribution without a wholesale distribution authorisation issued by the competent authority of the Member State in which they are established (Art 77). The holder of such an authorisation must always have available a responsible person possessing adequate professional qualifications. The authorisation specifies the site, categories of products, and conditions for supply. Competent authorities may conduct inspections of premises (Art 80) and demand that wholesale distributors maintain a recall plan, records tracing all supply and receipt of products, and an emergency plan for urgent recalls.
Wholesale distributors must comply with Good Distribution Practice (GDP) guidelines published by the Commission (Art 84). GDP covers quality management systems, personnel, premises and equipment, documentation, operations (receipt, storage, delivery, returns, counterfeits, complaints, recalls), outsourced activities, and self-inspection. Directive 2011/62/EC (the Falsified Medicines Directive) significantly reinforced GDP requirements by adding the safety features system (unique identifier + anti-tampering device) and strengthened supply-chain verification obligations for wholesale distributors (as amended).
Article 81 imposes the public service obligation (PSO) on wholesale distributors: the holder of a wholesale distribution authorisation for a product that is authorised in a Member State must maintain at all times an appropriate range of medicinal products to meet the requirements of patients in that territory, and supply those products within a very short time within the entire territory they cover. The PSO is the legal mechanism that prevents distributors from cherry-picking profitable products and abandoning slow-moving but medically necessary medicines. Member States may strengthen PSO requirements within their national law.
The ban on public advertising of prescription-only medicines, rules for HCP promotion, and inducement limits
Article 86 defines advertising broadly: all informational, canvassing or inducement activities intended to promote the prescription, supply, sale or consumption of medicinal products. The definition covers advertising to the general public, advertising to persons qualified to prescribe or supply medicines, visits by medical representatives, the supply of samples, sponsorship of promotional meetings, and scientific congresses.
Article 87 imposes the prohibition on advertising prescription-only medicines to the general public, and Art 87(2) extends the prohibition to medicines reimbursed by Member State health insurance schemes. Article 88 lists permitted disease-awareness campaigns (conducted by competent authorities), and Art 88(2) permits vaccination campaigns where the responsible competent authority approves the advertising materials. The ban on DTC (direct-to-consumer) advertising of prescription medicines is one of the most debated provisions of the Community Code.
All advertising of medicinal products to persons qualified to prescribe or supply must include the essential information compatible with the SmPC (Art 91), must state clearly that it is promotional material, and may not be misleading. Medical representatives must be adequately trained and must pass on information about adverse reactions (Art 93). Free samples may be supplied only in exceptional circumstances, only on written request from the prescriber, only by the sample holder, and limited in quantity (Art 96). Samples of narcotic or psychotropic substances are prohibited.
Persons qualified to prescribe or supply medicines may not solicit or accept any inducement, hospitality, financial benefit or benefit in kind from the pharmaceutical industry except where it is inexpensive and relevant to the practice of medicine or pharmacy (Art 94). The prohibition covers gift payments, consultancy fees that exceed fair market value, and educational grants tied to prescribing commitments. Member States may impose stricter provisions; several have enacted "sunshine" disclosure rules going beyond the directive's minimum harmonisation floor.
Member State PV systems, the MAH's qualified person, 15-day ADR reporting, PSURs, and EudraVigilance (as amended by Dir 2010/84)
Each Member State must establish a pharmacovigilance system to collect information on suspected adverse reactions, monitor the benefit-risk balance of authorised medicines, and take any regulatory action warranted. The competent authority must ensure that such reports are made accessible to the EMA and to the European pharmacovigilance data network (EudraVigilance). Member States must also encourage healthcare professionals and patients to report suspected adverse reactions through spontaneous reporting schemes (Art 102, as amended by Dir 2010/84).
The MA holder must have at their disposal a qualified person responsible for pharmacovigilance (QPPV) permanently and continuously available (Art 103). The QPPV must be resident and operating in the Community, must be responsible for establishing and maintaining the pharmacovigilance system, and is the contact point for regulatory authorities on all pharmacovigilance matters. The QPPV oversees the pharmacovigilance system master file, the risk management system, and PSUR submissions. Failure to have a QPPV in place is a ground for suspension of the MA.
The MA holder must report all suspected serious adverse reactions occurring within the Community and in third countries to the competent authority of the Member State on whose territory the reaction occurred and to EudraVigilance within 15 days of first receipt of the information (Art 104). Non-serious adverse reactions must be reported within 90 days. The 15-day clock applies to fatal, life-threatening and any other serious unexpected adverse reactions. Electronically submitted reports go directly to EudraVigilance as the central EU repository.
MA holders must submit Periodic Safety Update Reports (PSURs) to competent authorities and EudraVigilance at regular intervals reflecting the product's age: six-monthly for the first two years after initial authorisation, annually for the following two years (as amended by Dir 2010/84), and then five-yearly in line with the MA renewal cycle. PSURs contain a critical scientific evaluation of the benefit-risk balance, a listing of all adverse reactions, the current status of the SmPC, and the QPPV's assessment of whether changes to the authorisation terms are needed. The PRAC (added by Reg 1235/2010 + Dir 2010/84) leads the PSUR evaluation at Community level for medicines on the harmonised PSUR list.
The Community Code's original Title IX was substantially restructured by Directive 2010/84/EU and the parallel Regulation (EU) No 1235/2010. Key changes included: the creation of the Pharmacovigilance Risk Assessment Committee (PRAC) within the EMA; the establishment of the PSUR repository; the introduction of signal management through EudraVigilance; mandatory electronic ADR reporting by MA holders directly to EudraVigilance (bypassing national databases); the introduction of the list of medicines under additional monitoring (the "black triangle" scheme); and the requirement for MA holders to submit post-authorisation safety studies under risk management plans. A further amendment, Directive 2012/26/EU, added the "urgent Union procedure" following the benfluorex (Mediator) case.
Arts 109 to 130: the remaining five Titles rounding out the Community Code
Member States must take measures to promote voluntary unpaid blood and plasma donation and to achieve Community self-sufficiency in human blood and plasma (Art 109). Member States must take all necessary measures to prevent blood-borne infection from plasma-derived medicinal products; the MA holder is required to apply approved methods for inactivating viruses and to comply with any Community guidelines. Art 110 charges Member States with promoting voluntary unpaid donation.
Competent authorities must organise repeated inspections of manufacturers, importers and distributors (Art 111). They may take samples for testing and may examine documents. For vaccines, blood products and immunologicals, Art 114 requires official batch release: no batch may be distributed until it has been certified by a laboratory designated by the competent authority, with a maximum completion time of 60 days. Arts 116 to 119 set out grounds for suspension, revocation and variation of MAs, and the procedure for urgent public-health measures.
The Standing Committee on Medicinal Products for Human Use (comitology) assists the Commission in exercising its implementing powers under the directive (Art 120). The committee operates under the comitology procedure for delegated/implementing acts; Commission decisions adopted under the directive (e.g. binding arbitration decisions from CPMP referrals) pass through this standing committee. Art 121 is the enabling provision for the Commission to adapt Annexes and guidelines to technical and scientific progress.
Arts 122 to 124 require competent authorities of different Member States to cooperate, to exchange information, and to communicate decisions and assessment reports to the EMA and to each other. Art 125 requires all decisions by competent authorities to be reasoned and to indicate the possibility of appeal. Art 126 provides that the refusal or withdrawal of an MA in one Member State must be communicated to all other competent authorities. Art 127 enables the WHO-scheme export certificate: Member States must issue certificates confirming that a medicinal product has been authorised, at the manufacturer's request, for use in international regulatory applications.
Art 128 formally repeals the eleven codified predecessor directives, with Annex II Part B preserving their transposition deadlines so that no fresh national implementation obligation arose from the Code itself. Art 129 provides for entry into force (20 days after publication in the OJ). Art 130 addresses the addressees: the directive is addressed to the Member States. Together these three articles close the legislative instrument, tying the entire structure back to the recital 1 statement that 2001/83 is a codification in the interests of clarity, rationality and comprehensibility.
Core concepts from Title I and the directive text as used in EU medicines law
All figures read from the articles of Directive 2001/83/EC, as amended
| Parameter | Value | Legal basis | Notes |
|---|---|---|---|
| National MA procedure | 210 days | Art 17 | From valid application to decision; clock stops for applicant questions |
| Mutual-recognition recognition period | 90 days | Art 28 | Concerned Member States must recognise the RMS authorisation within 90 days |
| CPMP/CHMP referral opinion | 60 days | Art 32 | Extendable to 90 days in complex cases; binding Commission decision follows |
| Manufacturing authorisation (grant) | 90 days | Art 40(4) | Competent authority decision deadline from valid application |
| MA initial validity | 5 years | Art 24 | Renewable; unlimited after first renewal (as amended by Dir 2004/27) |
| Sunset clause (not marketed) | 3 years | Art 24(4) | MA lapses if product not placed on market within 3 years of grant |
| Sunset clause (withdrawn) | 3 years | Art 24(5) | MA lapses after 3 consecutive years absent from all Member State markets |
| Data exclusivity (generic route) | 8 years | Art 10(1) | As amended by Dir 2004/27; generic applicant may not file during this period |
| Market protection (generic route) | 10 years total | Art 10(1) | Generic cannot be placed on market until 10 years from initial innovator authorisation |
| +1 year for new indication | Up to 11 years | Art 10(1) | Where MA holder gains a significant new therapeutic indication within first 8 years |
| Serious ADR reporting | 15 days | Art 104 | From first receipt; fatal, life-threatening or other serious unexpected reactions |
| Non-serious ADR reporting | 90 days | Art 104 | Electronic submission to EudraVigilance (as amended by Dir 2010/84) |
| PSUR frequency (years 1-2) | Every 6 months | Art 104(6) | As amended; then annually for 2 years, then 5-yearly at renewal |
| Official batch release (vaccines etc.) | 60 days | Art 114 | Maximum time for official batch release certification by competent-authority lab |
Key milestones for Directive 2001/83/EC and its legal family
A directive is not directly applicable: each Member State must write it into its own national law by a transposition deadline. For the Community Code (Directive 2001/83/EC) the EU transposition deadline was inherited from the eleven codified directives of 1965 to 1992 (it is a consolidation; see Annex II Part B). The map shows, for each Member State, the principal national measure it notified to the Commission and its date. 23 of 27 Member States have notified measures parsed here; the full, authoritative list of national transposition measures for every Member State is on EUR-Lex (National transposition measures).
Click a Member State marker for the transposed national law and its publication date. Source: EUR-Lex National Implementing Measures, retrieved 26 May 2026. Where a marker reads "Notified via EUR-Lex", consult the EUR-Lex link above for that country's measures.
Key abbreviations and terms used throughout this page
Primary documentation for Directive 2001/83/EC
Six tools to analyse, track and work with EU pharmaceutical legislation